工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:An inducible signal 1 booster overcomes limited access to antigen for solid tumor cell therapy.
An inducible signal 1 booster overcomes limited access to antigen for solid tumor cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
抗原(信号1)是T细胞反应的引燃物和燃料。嵌合抗原受体(CAR)借用T细胞受体(TCR)信号结构域(例如ITAM元件)将T细胞反应重定向至特定抗原。大多数增强效力的尝试都添加了旨在保持抗原依赖性同时提高敏感性、持久性等的元件。然而,与血液肿瘤相比,实体瘤面临独特挑战。例如,进入表达靶抗原的肿瘤组织受到血管壁的高度限制,并且在抗原有限的情况下,尚不清楚如何使抗原依赖性增强元件发挥作用。在此,我们描述了一种简单的回路,通过用小分子模拟抗原刺激来增强CAR下游信号,从而解决这一问题。这些信号1增强元件是先前鉴定的MyD88-CD40融合蛋白的变体,但减轻了该分子过度的抗原敏化作用。我们鉴定出一种增强元件,当与CAR或Tmod共表达时,可产生小分子诱导的T细胞扩增和激活,同时在替代正常组织小鼠模型中保持良好的安全性特征。
Antigen (signal 1) is the ignition and fuel for T cell responses. Chimeric antigen receptors (CARs) co-opt T cell receptor (TCR) signaling domains (e. g. , ITAM elements) to redirect T cell responses to specific antigens. Most efforts to enhance potency have added elements intended to preserve antigen dependence while boosting sensitivity, persistence, etc.
However, solid tumors pose unique challenges compared to blood cancers. For example, access to tumor tissues that express target antigen is highly restricted by the blood vessel walls and, with limiting antigen, it is unclear how antigen-dependent boosters can be brought into action.
Here, we describe a simple circuit that addresses this problem by mimicking an antigen stimulus with a small molecule to boost signaling downstream of the CAR. These signal 1 boosters are variants of the previously identified MyD88-CD40 fusion protein but mitigate the excessive antigen sensitization of this molecule.
We identified a booster that, when expressed with CAR or Tmod, produces small-molecule-inducible T cell expansion and activation while maintaining a favorable safety profile in a surrogate normal-tissue mouse model.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。